| EPE0894 | Economic evaluation of scaling up HCV testing in men who have sex with men living with HIV and using PrEP in Taiwan | E-poster | Costing, cost effectiveness and affordability |
| EPE0895 | Determining the cost to provide an essential or comprehensive package of HIV interventions to key populations in Kenya | E-poster | Costing, cost effectiveness and affordability |
| EPE0896 | Economic assessment and evaluation of Medically Assisted Therapy (MAT) services in six counties in Kenya | E-poster | Costing, cost effectiveness and affordability |
| EPE0896 | Economic assessment and evaluation of Medically Assisted Therapy (MAT) services in six counties in Kenya | E-poster | Costing, cost effectiveness and affordability |
| OAE0302 | Long-acting HIV pre-exposure prophylaxis (PrEP) among adolescent girls and young women (AGYW) in South Africa: cost-effective at what cost? | Oral abstract session with live Q&A | Costing, cost effectiveness and affordability |
| OAE0303 | Predicted HIV acquisition rates for cabotegravir versus TDF/FTC as PrEP in Brazil: effects of compulsory licensing | Oral abstract session with live Q&A | Costing, cost effectiveness and affordability |
| OAE0305 | Cost-effectiveness of the WHO-endorsed advanced HIV care package in Malawi | Oral abstract session with live Q&A | Costing, cost effectiveness and affordability |
| OALBE0603 | Costs and cost-effectiveness of immediate initiation of antiretroviral therapy upon diagnosis of HIV (Rapid Start) in the United States | Oral abstract session with live Q&A | Costing, cost effectiveness and affordability |
| TUPEE04 | The cost and intermediate cost-effectiveness of delivering U=U messaging to increase HIV testing among South African men | Poster exhibition | Costing, cost effectiveness and affordability |
| EPB0108 | A description of the characteristics and causes of HIV related in-patient mortalities at two tertiary children’s hospitals in Zambia for the period January – December 2021 | E-poster | Course of HIV disease |